90岁及以上缺血性卒中患者的静脉溶栓治疗:TRISP协作组队列研究
这项来自TRISP登记的前瞻性多中心研究比较了976例≥90岁与<90岁缺血性卒中患者静脉溶栓后的结局。≥90岁组症状性颅内出血发生率与<90岁组无显著差异(5.7% vs 4.4%,调整OR 1.14 [0.83-1.57]),但死亡(调整OR 3.77 [3.14-4.53])和不良功能结局(调整OR 2.63 [2.13-3.25])更高。百岁老人亚组(n=21)结果相似。作者认为极高龄本身不应成为拒绝静脉溶栓的理由。
要点
- ≥90岁卒中患者静脉溶栓后症状性颅内出血风险与年轻患者无显著差异。
- ≥90岁患者死亡和不良功能结局风险更高,但似乎与溶栓治疗无关。
- 极高龄本身不应成为不进行静脉溶栓的理由。
核心结论
- 极高龄卒中患者静脉溶栓后症状性颅内出血概率未超过较年轻患者,随访期间死亡和不良功能结局概率更高似乎与溶栓治疗无关,极高龄本身不应成为不进行静脉溶栓的理由。
研究设计与样本
- TRISP登记的前瞻性多中心研究,共纳入16974例符合条件的静脉溶栓患者,其中976例(5.7%)年龄≥90岁,比较≥90岁与<90岁患者的结局。
主要发现
- ≥90岁组入院时美国国立卫生研究院卒中量表评分中位数更高(12 vs 8),卒中前依赖(改良Rankin量表评分≥3)比例更高(45.2% vs 7.4%)。
- 症状性颅内出血发生率≥90岁组5.7% vs <90岁组4.4%,调整OR 1.14(95%CI 0.83-1.57),两组无显著差异。
- 死亡概率≥90岁组调整OR 3.77(95%CI 3.14-4.53),高于<90岁组。
- 不良功能结局概率≥90岁组调整OR 2.63(95%CI 2.13-3.25),高于<90岁组。
- 百岁老人亚组(n=21)结果相似。
关键数值与推荐
- 症状性颅内出血采用ECASS-II标准定义。
- 不良功能结局定义:卒中前改良Rankin量表评分≤2的患者为随访3个月时改良Rankin量表评分3-5,卒中前改良Rankin量表评分≥3的患者为随访3个月时改良Rankin量表评分4-5。
临床怎么用
- 作者认为极高龄本身不应成为不进行静脉溶栓的理由。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The probability to receive intravenous thrombolysis (IVT) for treatment of acute ischemic stroke declines with increasing age and is consequently the lowest in very elderly patients. Safety concerns likely influence individual IVT treatment decisions. Using data from a large IVT registry, we aimed to provide more evidence on safety of IVT in the very elderly. METHODS: In this prospective multicenter study from the TRISP (Thrombolysis in Ischemic Stroke Patients) registry, we compared patients ≥90 years with those <90 years using symptomatic intracranial hemorrhage (ECASS [European Cooperative Acute Stroke Study]-II criteria), death, and poor functional outcome in survivors (modified Rankin Scale score 3-5 for patients with prestroke modified Rankin Scale score ≤2 and modified Rankin Scale score 4-5 for patients prestroke modified Rankin Scale ≥3) at 3 months as outcomes. We calculated adjusted odds ratio with 95% CI using logistic regression models. RESULTS: Of 16 974 eligible patients, 976 (5.7%) were ≥90 years. Patients ≥90 years had higher median National Institutes of Health Stroke Scale on admission (12 versus 8) and were more often dependent prior to the index stroke (prestroke modified Rankin Scale score of ≥3; 45.2% versus 7.4%). Occurrence of symptomatic intracranial hemorrhage (5.7% versus 4.4%, odds ratioadjusted 1.14 [0.83-1.57]) did not differ significantly between both groups. However, the probability of death (odds ratioadjusted 3.77 [3.14-4.53]) and poor functional outcome (odds ratioadjusted 2.63 [2.13-3.25]) was higher in patients aged ≥90 years. Results for the sample of centenarians (n=21) were similar. CONCLUSIONS: The probability of symptomatic intracranial hemorrhage after IVT in very elderly patients with stroke did not exceed that of their younger counterparts. The higher probability of death and poor functional outcome during follow-up in the very elderly seems not to be related to IVT treatment. Very high age itself should not be a reason to withhold IVT.
引用
- Altersberger VL, Rusche N, Martinez-Majander N, et al. Intravenous Thrombolysis in Patients With Ischemic Stroke Aged ≥90 Years: A Cohort Study From the TRISP Collaboration. Stroke. 2022. PMID: 36252105. doi:10.1161/STROKEAHA.122.039426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。